Compare · SYK vs XENT
SYK vs XENT
Side-by-side comparison of Stryker Corporation (SYK) and Intersect ENT Inc. (XENT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYK and XENT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK carries a market cap of $121.12B.
- SYK has hit the wire 12 times in the past 4 weeks while XENT has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 5 for XENT).
- Company
- Stryker Corporation
- Intersect ENT Inc.
- Price
- -
- -
- Market cap
- $121.12B
- -
- 1M return
- +5.35%
- -
- 1Y return
- -13.99%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 5
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Intersect ENT Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Latest SYK
- Director Stryker Ronda E sold $178,924,731 worth of shares (550,000 units at $325.32) (SEC Form 4)
- Stryker Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Stryker announces intention to nominate Jim Davis to board of directors
- What 3.4% GDP Growth and a 4.2% Jobless Rate Say About a Hard Day on Wall Street
- SEC Form S-3ASR filed by Stryker Corporation
- SEC Form IRANNOTICE filed by Stryker Corporation
- SEC Form 10-Q filed by Stryker Corporation
- Stryker downgraded by Canaccord Genuity with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker reports third quarter 2026 operating results
Latest XENT
- FDA Approval for SINUVA issued to INTERSECT ENT INC
- SEC Form POSASR filed by Intersect ENT Inc.
- SEC Form RW WD filed by Intersect ENT Inc.
- Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
- SEC Form 15-12B filed by Intersect ENT Inc.
- SEC Form S-8 POS filed by Intersect ENT Inc.
- SEC Form EFFECT filed by Intersect ENT Inc.
- SEC Form 4 filed by Hattangadi Neil A
- SEC Form 4: Meier Richard A closing all direct ownership in the company
- SEC Form 4: Fernandez Reyna M closing all direct ownership in the company